Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombolytic therapy for acute ischemic stroke.

R E Kelley1

  • 1Department of Neurology, Louisiana State University Health Sciences Center, Shreveport, USA.

The Journal of the Louisiana State Medical Society : Official Organ of the Louisiana State Medical Society
|June 30, 2000
PubMed
Summary

Recombinant tissue plasminogen activator (rt-PA) effectively treats acute ischemic stroke within 3 hours, improving recovery chances by 30%. However, rt-PA increases the risk of symptomatic intracerebral hemorrhage.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obstructive sleep apnea intensifies stroke severity following middle cerebral artery occlusion.

Sleep medicine·2020
Same author

Combined antithrombotic therapy of potential value in acute atrial fibrillation related stroke.

European journal of neurology·2014
Same author

Interferon (IFN)-beta 1a and IFN-beta 1b block IFN-gamma-induced disintegration of endothelial junction integrity and barrier.

Endothelium : journal of endothelial cell research·2004
Same author

Magnetic resonance imaging detection of a lesion compatible with central pontine myelinolysis in a pregnant patient with recurrent vomiting and confusion.

Journal of neuroimaging : official journal of the American Society of Neuroimaging·2001
Same author

Stroke in the postoperative period.

The Medical clinics of North America·2001
Same author

Difficult prenatal diagnosis in mild Smith-Lemli-Opitz syndrome.

American journal of medical genetics·2001

Area of Science:

  • Neurology
  • Emergency Medicine
  • Radiology

Background:

  • Acute ischemic stroke requires timely intervention for optimal outcomes.
  • Recombinant tissue plasminogen activator (rt-PA) is a key thrombolytic agent.
  • Treatment decisions involve balancing benefits against risks, including hemorrhage.

Purpose of the Study:

  • To evaluate the efficacy and safety of rt-PA in acute ischemic stroke.
  • To define the critical time window and contraindications for rt-PA administration.
  • To assess the risk of hemorrhagic transformation associated with rt-PA.

Main Methods:

  • Review of clinical guidelines and treatment protocols for acute ischemic stroke.
  • Mandatory use of non-contrast CT brain scans to exclude hemorrhage and assess infarct evolution.

Related Experiment Videos

  • Analysis of patient outcomes, including recovery rates and incidence of symptomatic intracerebral hemorrhage.

    • Main Results:

    • rt-PA treatment within 3 hours of stroke onset improves full recovery chances by approximately 30% at 3 months.
    • Delayed treatment within the 3-hour window reduces clinical benefit and increases hemorrhagic transformation risk.
    • Symptomatic intracerebral hemorrhage occurs in 6.4% of rt-PA treated patients versus 0.6% in placebo, particularly with greater neurological deficits and infarct evolution.

    Conclusions:

    • rt-PA is an accepted treatment for acute ischemic stroke within a 3-hour window when indicated and without contraindications.
    • Non-contrast CT is essential for patient selection and risk assessment.
    • The risk of intracerebral hemorrhage increases with delayed treatment, greater neurological deficits, and advanced infarct evolution.